Mon panier

Human IL-31 Protein, His Tag, low Endotoxin (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
IL1-H5247-100ug
$470.00
IL1-H5247-1mg (500ug X 2)
$3335.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    IL-31, IL31, Interleukin-31

  • Source

    Human IL-31, His Tag (IL1-H5247) is expressed from human 293 cells (HEK293). It contains AA Ser 24 - Thr 164 (Accession # Q6EBC2-1).

    Predicted N-terminus: His

    Request for sequence
  • Molecular Characterization

    IL-31 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the N-terminus.

    The protein has a calculated MW of 17.7 kDa. The protein migrates as 22-25 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 0.01 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    IL-31 SDS-PAGE

    Human IL-31, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    IL-31 SEC-MALS

    The purity of Human IL-31, His Tag (Cat. No. IL1-H5247) is more than 95% and the molecular weight of this protein is around 15-25 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     IL-31 ELISA

    Immobilized Human IL-31, His Tag (Cat. No. IL1-H5247) at 1 μg/mL (100 μL/well) can bind Human IL-31 RA, Fc Tag (Cat. No. ILA-H5256) with a linear range of 0.02-0.625 μg/mL (QC tested).

    Protocol
  • Bioactivity-SPR

     IL-31 SPR

    Human IL-31, His Tag (Cat. No. IL1-H5247) immobilized on CM5 Chip can bind Human IL-31 RA, His Tag (Cat. No. ILA-H52H7) with an affinity constant of 52.1 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  •  IL-31 SPR

    Human IL-31, His Tag (Cat. No. IL1-H5247) capture on NTA-Series S sensor chip can bind Human IL-31 RA, Fc Tag (Cat. No. ILA-H5256) with an affinity constant of 37.1 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

IL-31 is an inflammatory cytokine that helps trigger cell-mediated immunity against pathogens. Activates STAT3 and possibly STAT1 and STAT5 through the IL31 heterodimeric receptor composed of IL31RA and OSMR. It has also been identified as a major player in a number of chronic inflammatory diseases, including atopic dermatitis. May function in skin immunity. IL-31 is produced by a variety of cells, namely type 2 helper (TH2) T-cells. IL-31 sends signals through a receptor complex made of IL-31RA and oncostatin M receptor β (OSMRβ) expressed in immune and epithelial cells. These signals activate three pathways: ERK1/2 MAP kinase, PI3K/AKT, and JAK1/2 signaling pathways.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Interleukin-31

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    5 Détails

  • Étape de développement la plus élevée:

    Phase 2 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte